Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Pulocimab and Paclitaxel in Advanced Gastric/GEJ Cancer
NCT06341335Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab, pulocimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Jun 2024; status: recruiting.
02
Drugs
cadonilimabpulocimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06341335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341335.